Kieran Gallahue is Chairman and Chief Executive Officer of CareFusion. Previously, Kieran served as President, CEO and a Director of ResMed, a global leader in medical equipment for treating, diagnosing and managing sleep-related respiratory disorders. Kieran joined ResMed in 2003 as President and Chief Operating Officer, Americas, was promoted to the role of President and COO of ResMed Global in 2004 and CEO and Director in 2008. Prior to joining ResMed, Kieran held positions of increasing responsibility at Nanogen, a DNA research and medical diagnostics firm, and Instrumentation Laboratory, a leader in diagnostic instruments for critical care and hemostatsis. He has also held marketing, sales and financial roles at Procter & Gamble Company and GE. Kieran serves on the Board of Directors and Executive Committee of AdvaMed, the Advanced Medical Technology Association, and also serves as the Chairman of Advamed’s International Committee. Kieran holds a B.A. in Economics and Accounting from Rutgers University and an M.B.A. from Harvard Business School.
Lesley H. Howe
Lesley H. Howe was appointed to the Board of Directors in October 2005. Since December 2001, he has served as Chief Executive Officer at Consumer Networks LLC, an Internet marketing and promotions company. Mr. Howe currently serves on the Board of Directors of dj Orthopedics, Inc., a medical technology company, P.F. Chang's China Bistro, Inc., an owner and operator of restaurants, and NuVasive, Inc., a medical technology company. From July 1967 to September 1997, Mr. Howe held several positions at KPMG Peat Marwick LLP, an international auditing and accounting firm, and served as area managing partner/managing partner of their Los Angeles office from May 1994 to September 1997. Mr. Howe holds a B.S. in Accounting from the University of Arkansas and is a certified public accountant.
Scott Huennekens
Scott Huennekens has served as President and Chief Executive Officer since April 2002. Previously, he served as the President and Chief Executive Officer of Digirad Corporation, a medical imaging company from 2000 to 2002. He joined Digirad as a start-up in 1997 as Chief Operating Officer and was promoted to President and CEO and the Board of Directors in 2000. From 1993 to 1997, he worked at Baxter International, Inc. in the Edwards Cardiovascular Division with increasing responsibilities including Vice President of Sales and Marketing for the Novacor division. Mr. Huennekens is a member of the Board of Directors for Volcano Corporation, Scripps Translational Science Institute, the Medical Device Manufacturers Association (MDMA), BIOCOM, and the University of Southern California Marshall School of Business. He received a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard Business School.
Siddhartha Kadia
Siddhartha Kadia has served as a member of our Board of Directors since March 2013. Since April 2013, Dr. Kadia has served as President of the Life Sciences Division of Life Technologies Corporation, a publicly-traded global biotechnology company. From April 2011 to April 2013, Dr. Kadia served as President of Life Technologies Greater China, a subsidiary of Life Technologies Corporation. Prior to that, Dr. Kadia served in various executive roles at Life Technologies, including the President of Life Technologies Japan Ltd. and Chief Marketing Officer. From July 2005 to July 2008, he served in numerous roles at Invitrogen Corporation, a publicly-traded biotechnology company that was merged with Applied Biosystems, Inc. in 2008 to form Life Technologies, including most recently as Vice President of Global Marketing and eBusiness. Before joining Invitrogen Corporation in 2005, Dr. Kadia was a management consultant at McKinsey & Company where his work focused on various healthcare related engagements: assisting medical device companies from the US and Europe in developing strategic direction and improving earnings, advising several local and state governments in the U.S. on healthcare spend effectiveness and consulting with several medium and large U.S. healthcare providers in improving profitability. Prior to McKinsey, Dr. Kadia was a post-doctoral fellow at Johns Hopkins University School of Medicine. Dr. Kadia grew up in India and has lived and worked in the U.S., Europe, Japan and China. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University, a Master’s of Biomedical Engineering from Rutgers University and a B.E. in Electronics and Telecommunications from Gujarat University in India.
Alexis V. Lukianov
Alexis V. Lukianov was appointed to the Board of Directors in December 2007. Since July 1999, Mr. Lukianov has served NuVasive, Inc as its President, Chief Executive Officer and a director, and since February 2004, Mr. Lukianov has served as Chairman of the Board and Chief Executive Officer. NuVasive, Inc. is a publicly-traded medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. From April 1996 to April 1997, Mr. Lukianov was a founder of and served as Chairman of the Board and Chief Executive Officer of BackCare Group, Inc., a spine physician practice management company. From January 1990 to October 1995, Mr. Lukianov held a variety of senior executive positions including president with Medtronic Sofamor Danek, Inc., a developer and manufacturer of medical devices to treat disorders of the cranium and spine, and a subsidiary of Medtronic, Inc., a publicly-traded medical technology company. Mr. Lukianov has over 20 years of successful experience in the orthopedic industry including various positions with the orthopedics division of Smith and Nephew and also a joint venture between Meadox Medicals, Inc. (Boston Scientific) and Stryker Corporation orthopedics. Mr. Lukianov serves on the boards of NuVasive, Inc., California Health Institute, BIOCOM, Medical Device Manufacturers Association and Ophthonix, Inc., a privately-held company focused on vision correction technology.
Ronald A. Matricaria
Ronald A. Matricaria was appointed to the Board of Directors in October 2005. He served as Chairman of St. Jude Medical, Inc. from January 1995 to December 2002, and as President and Chief Executive Officer from April 1993 to May 1999. Mr. Matricaria currently serves on the boards of directors of Life Technologies Corporation, a life sciences company and Hospira, Inc., a specialty pharmaceuticals company. He is also Trustee emeritus of the University of Minnesota Foundation. Mr. Matricaria holds a bachelor's degree from the Massachusetts College of Pharmacy and was awarded an honorary doctorate degree in Pharmacy in recognition of his contribution to the practice of pharmacy.
Leslie V. Norwalk, Esq.
Leslie Norwalk is Strategic Counsel to Epstein Becker & Green, P.C., EBG Advisors and National Health Advisors. She serves as an advisor to three private equity firms: Warburg Pincus, Ferrer Freeman & Company, and Enhanced Equity Fund, and sits on the boards of directors of Sound Physicians, Guardian Healthcare Group, Sante Pediatric Rehabilitation, IkaSystems, MTS Medication Technologies, InHealth, Press Ganey, and the International Advisory Board of APCO Worldwide.
Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. For four years prior to that, she was the agency's Deputy Administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. CMS has the second-largest budget outlay of the Federal Government, directly responsible for $1 out of every $3 spent on healthcare in the United States. The organization insures nearly a third of the population of the United States (more than 95 million beneficiaries) including the elderly, disabled, and some of the lowest income individuals in the country. CMS processes over one billion claims each year and contracts with approximately one million providers.
Prior to serving the Bush Administration, she practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative.
Ms. Norwalk, a native of Dayton, OH, earned a juris doctor degree from the George Mason University School of Law, where she was a Dean's Scholar and an editor of the George Mason Law Review. She earned a bachelor's degree, cum laude, in economics and international relations from Wellesley College.
Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. For four years prior to that, she was the agency's Deputy Administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. CMS has the second-largest budget outlay of the Federal Government, directly responsible for $1 out of every $3 spent on healthcare in the United States. The organization insures nearly a third of the population of the United States (more than 95 million beneficiaries) including the elderly, disabled, and some of the lowest income individuals in the country. CMS processes over one billion claims each year and contracts with approximately one million providers.
Prior to serving the Bush Administration, she practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative.
Ms. Norwalk, a native of Dayton, OH, earned a juris doctor degree from the George Mason University School of Law, where she was a Dean's Scholar and an editor of the George Mason Law Review. She earned a bachelor's degree, cum laude, in economics and international relations from Wellesley College.
Roy T. Tanaka
Roy T. Tanaka was appointed to the Board of Directors in April 2009. From 2004 through 2008, Mr. Tanaka served as the Worldwide President of Biosense Webster, Inc. for Johnson & Johnson. Mr. Tanaka joined Johnson & Johnson as the U.S. President of Biosense Webster, Inc. in 1997. From 1992 to 1997, he served in a variety of senior management positions at Sorin Biomedical, Inc., including President and Chief Executive Officer. From 1989 to 1992, Mr. Tanaka served in Vice President roles with Shiley, a division of Pfizer Inc. Mr. Tanaka received a B.S. in Mechanical Engineering from Purdue University and an M.B.A. from Illinois Benedictine College.
Eric J. Topol, MD
Dr. Topol is a pioneer of the genomic and wireless digital innovative technologies to reshape the future of medicine.
He is a practicing cardiologist at Scripps in La Jolla, California and well known for leading the Cleveland Clinic to become the #1 center for heart care. While there he also started a new medical school, led many worldwide clinical trials to advance care for patients with heart disease, and spearheaded the discovery of multiple genes that increase susceptibility for heart attacks.
Since 2006, in La Jolla, he leads the flagship NIH supported Scripps Translational Science Institute and is a co-Founder and the Vice-Chairman of the West Wireless Health Institute. He also serves as Professor of Genomics at The Scripps Research Institute and Chief Academic Officer of Scripps Health.
Topol pioneered the development of many medications that are routinely used in medical practice including t-PA, Plavix, Angiomax, and ReoPro and was the first physician to raise safety concerns on Vioxx. He has published 1100 peer-reviewed articles and over 30 medical textbooks. In 2009, along with Francis Collins and Harold Varmus, Topol was selected to be one of the country’s 12 “Rock Stars of Science” in GQ Magazine . In 2011, the University of Michigan, where he had served on the faculty, initiated the Eric Topol Professor of Cardiovascular Medicine to recognize his contributions. The University of Rochester, his alma mater medical school, awarded him the Hutchinson Medal, the University’s highest honor.
He was named as one of the Top 100 Most Influential People in Healthcare in 2011.
He was elected to the Institute of Medicine of the National Academy of Sciences and is one of the top 10 most cited researchers in medicine. His book The Creative Destruction of Medicine (Basic Books) was published in 2012.
He is a practicing cardiologist at Scripps in La Jolla, California and well known for leading the Cleveland Clinic to become the #1 center for heart care. While there he also started a new medical school, led many worldwide clinical trials to advance care for patients with heart disease, and spearheaded the discovery of multiple genes that increase susceptibility for heart attacks.
Since 2006, in La Jolla, he leads the flagship NIH supported Scripps Translational Science Institute and is a co-Founder and the Vice-Chairman of the West Wireless Health Institute. He also serves as Professor of Genomics at The Scripps Research Institute and Chief Academic Officer of Scripps Health.
Topol pioneered the development of many medications that are routinely used in medical practice including t-PA, Plavix, Angiomax, and ReoPro and was the first physician to raise safety concerns on Vioxx. He has published 1100 peer-reviewed articles and over 30 medical textbooks. In 2009, along with Francis Collins and Harold Varmus, Topol was selected to be one of the country’s 12 “Rock Stars of Science” in GQ Magazine . In 2011, the University of Michigan, where he had served on the faculty, initiated the Eric Topol Professor of Cardiovascular Medicine to recognize his contributions. The University of Rochester, his alma mater medical school, awarded him the Hutchinson Medal, the University’s highest honor.
He was named as one of the Top 100 Most Influential People in Healthcare in 2011.
He was elected to the Institute of Medicine of the National Academy of Sciences and is one of the top 10 most cited researchers in medicine. His book The Creative Destruction of Medicine (Basic Books) was published in 2012.